<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90850">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081053</url>
  </required_header>
  <id_info>
    <org_study_id>DF-13-03</org_study_id>
    <nct_id>NCT02081053</nct_id>
  </id_info>
  <brief_title>Evaluating Clinical Outcomes of the STAR and StabiliT Systems to Treat Painful Metastatic Vertebral Body Tumors in the Spine</brief_title>
  <acronym>EU-STAR</acronym>
  <official_title>A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of the STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System to Treat Painful Metastatic Vertebral Body Tumor(s) in the Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DFINE Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DFINE Inc.</source>
  <oversight_info>
    <authority>Germany: Ethics Committees</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical outcomes of minimally invasive targeted radiofrequency tumor
      ablation (t-RFA) and vertebral augmentation in metastatic lesions in the spine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Numerical Rating Pain Scale (NRPS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in function</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Modified Oswestry Low Back Pain Disability Questionnaire (m-ODI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>up to  6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by European Organization for Research and Treatment of Cancer and Bone Metastasis Questionnaires  (EORTC-C30 and EORTC-BM22)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain medications</measure>
    <time_frame>up to  6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Lesions in Vertebral Bodies</condition>
  <arm_group>
    <arm_group_label>RF Ablation and Vertebral Augmentation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STAR™ Tumor Ablation System  and StabiliT® Vertebral Augmentation System</intervention_name>
    <description>Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)</description>
    <arm_group_label>RF Ablation and Vertebral Augmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of metastatic lesion by MRI at T1 to L5 in 1-3 vertebra

          -  Pain score  ≥  6 on the numerical rating pain scale

          -  Moderate Disability (21%-40%) on Oswestry Disability Index

        Exclusion Criteria:

          -  Primary tumors of the bone at index vertebra

          -  Osteoblastic tumors at index vertebra

          -  Index vertebra with more than one (1) pedicle involved

          -  Index vertebra with epidural extension of tumor resulting in spinal cord compression
             as evidenced by MRI

          -  Radiation therapy is planned to be started on the index vertebra within 2 weeks post
             procedure

          -  Radiation therapy was performed on the index vertebra within 2 months before
             enrollment

          -  Major surgery of the spine was performed within 3 months before enrollment

          -  Index vertebra(e) had previous spine surgery including vertebroplasty or kyphoplasty

          -  Additional non-kyphoplasty/vertebroplasty surgical treatment is required for the
             index vertebra
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Vogl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe-Universität Frankfurt am Main</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nouvel Höpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion Vazel</last_name>
      <email>marion.vazel@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Afshin Gangi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rahel Bornemann, MD</last_name>
      <phone>004915158233889</phone>
      <email>rahel.bornemann@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Pflughmacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Hammerstingl</last_name>
      <email>hammerstingl@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Vogl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarete Wicharz</last_name>
      <email>margarete.wicharz@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Kourosh Zarghooni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Joellenbeck, MD</last_name>
      <email>boris.joellenbeck@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Boris Joellenbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic lesions</keyword>
  <keyword>vertebral body</keyword>
  <keyword>ablation</keyword>
  <keyword>targeted radio-frequency ablation</keyword>
  <keyword>radio-frequency targeted vertebral augmentation</keyword>
  <keyword>radiofrequency kyphoplasty</keyword>
  <keyword>spine</keyword>
  <keyword>vertebral augmentation</keyword>
  <keyword>kyphoplasty</keyword>
  <keyword>spinal ablation</keyword>
  <keyword>pain</keyword>
  <keyword>quality of life</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
